CSTP1 inhibits IL-6 expression through targeting Akt/FoxO3a signaling pathway in bladder cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• CSTP1 (CSTP1) is a protein phosphatase often repressed in bladder cancer.
• CSTP1 overexpression inhibits cell cycle and promotes apoptosis in bladder cancer cells by dephosphorylating Akt kinase.
• The precise tumor-suppressive mechanisms of CSTP1 remain incompletely understood.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying CSTP1's tumor suppressive activity in bladder cancer.
• To investigate the relationship between CSTP1, Interleukin-6 (IL-6), and key signaling pathways involved in cancer progression.

Main Methods:

• Microarray analysis to assess gene expression changes upon CSTP1 overexpression.
• Investigation of IL-6 expression and secretion in bladder cancer cells.
• Analysis of FoxO3a binding to the IL-6 promoter.
• Assessment of Stat3 activation and downstream target gene expression (cyclin D1, Bcl-xl).
• Spearman correlation analysis of CSTP1 and IL-6 mRNA levels in patient tissues.

Main Results:

• CSTP1 overexpression significantly decreased IL-6 expression and secretion in bladder cancer cells.
• Re-expression of IL-6 counteracted the tumor-suppressive effects of CSTP1.
• FoxO3a was identified as a repressor of IL-6 transcription by binding to its promoter.
• CSTP1-mediated IL-6 reduction inactivated Stat3, leading to decreased cyclin D1 and Bcl-xl expression.
• Inverse correlation observed between CSTP1 and IL-6 mRNA levels in bladder cancer tissues.

Conclusions:

• Protein phosphatase CSTP1 inhibits IL-6 expression through the Akt/FoxO3a signaling pathway.
• IL-6 inactivation of Stat3 is essential for CSTP1's tumor suppressive function in bladder cancer.
• CSTP1 acts as a tumor suppressor by modulating the IL-6/Stat3 axis.